Journal of the European Academy of Dermatology and Venereology· 2026Q1· Review
Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline
- 0citations
- Q1SCImago
- 2026year
Short summary
Novel treatments for hidradenitis suppurativa (HS) are targeting key inflammatory pathways (IL-17, IL-1, TNF, JAK, TYK2) and innate immune mechanisms, with emerging biologics, dual-inhibition strategies, and oral small-molecule inhibitors showing promise.
AI-generated from the title and abstract; the full text is not read.
Key points
- Novel HS treatments focus on IL-17, IL-1, TNF, JAK, and TYK2 inflammatory pathways.
- Emerging therapies include biologics, dual-cytokine inhibitors, bispecific agents, and oral small-molecule inhibitors.
- Alternative targets include B-cell modulation, complement, chemokine signaling, and intracellular pathways.
- Clinical trial results for new HS treatments are heterogeneous, with some trials not meeting endpoints.
AI-generated from the title and abstract; the full text is not read.
Abstract
Recent developments in hidradenitis suppurativa (HS) have focused on targeting key inflammatory pathways implicated in the pathogenesis of the disease, including interleukin (IL)-17, IL-1, tumour necrosis factor (TNF), Janus kinase (JAK) and tyrosine kinase 2 (TYK2) signalling as well as innate immune mechanisms such as neutrophil activation and complement pathways. Novel biologics, dual cytokine-inhibition strategies and bispecific agents represent an emerging therapeutic paradigm. Small-molecule inhibitors, including JAK1 and TYK2 inhibitors, offer the potential advantage of oral administration and broader immunomodulatory effects. Therapies targeting alternative mechanisms, including B-cell modulation, complement inhibition, chemokine signalling and intracellular pathways, are also being actively investigated. While some agents have shown encouraging results in selected HS trials, including responses at higher thresholds, such as IHS4-75 or IHS4-90, findings remain heterogeneous. Some trials have not met their primary endpoints, highlighting the challenges of translating mechanistic rationale into consistent clinical benefit. Overall, the expanding therapeutic pipeline in HS reflects a shift towards precision medicine and pathway-specific interventions. This review aims to summarize the upcoming treatments in hidradenitis suppurativa and to outline the future therapeutic landscape of the disease.
The authors' abstract, as published at the source. Journal of the European Academy of Dermatology and Venereology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Dermatology
DermatologyMedicine